Neurodegeneration

Understanding neurodegeneration is key to developing and taking forward new treatments for Alzheimer's disease, Parkinson's disease and stroke. Central to our approach is translating basic science into improved clinical treatment. Key elements of our work include experimental studies to understand basic disease mechanisms, the Brains for Dementia Research initiative, enabling us to apply this understanding to the human brain, and a substantial focus on biomarkers and clinical trials. Major clinical trials have addressed psychiatric and behavioural symptoms associated with dementia and the use of antipsychotic and sedative drugs. The Neurodegeneration group is led by Professor Clive Ballard.